Last reviewed 2026-05-23 · How we verify

Ravidasvir test formulation produced by Doppel

Drugs for Neglected Diseases · Phase 1 active Small molecule ✓ Verified May 2026 Quality 0/100

Ravidasvir test formulation produced by Doppel is a Small molecule drug developed by Drugs for Neglected Diseases. It is currently in Phase 1 development.

Ravidasvir test formulation produced by Doppel was studied in a Phase 1 bioequivalence trial to compare its effects with the reference formulation produced by EEPI. The trial, conducted by Drugs for Neglected Diseases, aimed to evaluate the bioequivalence of the test formulation with the reference formulation in healthy participants.

Likelihood of approval

9.6% vs 9.6% industry baseline

If approved by FDA: likely 2033–2036

Steps remaining: Phase 2 → Phase 3 → NDA/BLA submission

Confidence: Medium

Why this estimate

Baseline phase 1 → approval rate +9.6pp
Industry-wide phase 1 drugs reach approval ~9.6% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).

Predicted approval windows by jurisdiction (conditional on FDA approval)

Regulator	Country	Likely year	Lag vs FDA
FDA	US	2033–2036	—
EMA	EU	2034–2037	+0.7 yr
MHRA	GB	2034–2037	+0.7 yr
Health Canada	CA	2034–2038	+0.9 yr
TGA	AU	2034–2038	+1.2 yr
PMDA	JP	2034–2038	+1.5 yr
NMPA	CN	2035–2039	+2.3 yr
MFDS	KR	2034–2038	+1.4 yr
CDSCO	IN	2034–2039	+1.8 yr
ANVISA	BR	2035–2039	+2.3 yr

Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).

Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.

At a glance

Generic name	Ravidasvir test formulation produced by Doppel
Sponsor	Drugs for Neglected Diseases
Modality	Small molecule
Phase	Phase 1

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

A Phase 1 Bioequivalence Study of a Test Tablet Formulation of Ravidasvir With the Reference Tablet Formulation of Ravidasvir Study (PHASE1)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Ravidasvir test formulation produced by Doppel CI brief — competitive landscape report
Ravidasvir test formulation produced by Doppel updates RSS · CI watch RSS
Drugs for Neglected Diseases portfolio CI

Frequently asked questions about Ravidasvir test formulation produced by Doppel

What is Ravidasvir test formulation produced by Doppel?

Ravidasvir test formulation produced by Doppel is a Small molecule drug developed by Drugs for Neglected Diseases.

Who makes Ravidasvir test formulation produced by Doppel?

Ravidasvir test formulation produced by Doppel is developed by Drugs for Neglected Diseases (see full Drugs for Neglected Diseases pipeline at /company/drugs-for-neglected-diseases).

What development phase is Ravidasvir test formulation produced by Doppel in?

Ravidasvir test formulation produced by Doppel is in Phase 1.

Manufacturer: Drugs for Neglected Diseases — full pipeline

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing